International Patent: THE USE OF TAAR1 AGONISTS SUCH AS ULOTARONT, DEPRENYL OR BENZOFURANYLPROPYLAMINOPENTANE TO INCREASE DOPAMINE IN THE RETINA TO TREAT OCULAR DISORDERS

GENEVA, Sept. 24 -- SEMMELWEIS EGYETEM filed a patent application (HU2025/050081) for “THE USE OF TAAR1 AGONISTS SUCH AS ULOTARONT, DEPRENYL OR BENZOFURANYLPROPYLAMINOPENTANE TO INCREASE DOPAMINE IN THE RETINA TO TREAT OCULAR DISORDERS”. With publication no. WO/2026/196013, here are the other details related to the patent application:

Kind: Initial Publication with ISR [A1]

IPC: A61K 31/381

Notably, the patent application was submitted under the International Patent Classification (IPC) system, which is managed by the World Intellectual Property Organization (WIPO).

Disclaimer: Curated by HT Syndication....